UBS Upgrades Zimmer Biomet Stock to 'Buy' with Raised Price Target
Zimmer Biomet (NYSE: ZBH) saw its stock rise on Tuesday following an upgrade by UBS analyst Patrick Wood, who moved the rating from Sell to Buy. The change was based on positive growth expectations and innovation within the orthopedic product sector. Wood also adjusted his price target for Zimmer Biomet's shares upward, increasing it from $89 to $115. This reflects a more optimistic outlook regarding the company’s future performance.
Tickers: $ZBH
Topics: stock price target change UBS analyst upgrade Zimmer Biomet